- Home
- CANF vs RVLV Comparison
CANF vs RVLV Comparison
Compare CANF & RVLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- RVLV
- Stock Information
- Founded
- CANF 1994
- RVLV 2003
- Country
- CANF Israel
- RVLV United States
- Employees
- CANF N/A
- RVLV N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- RVLV Catalog/Specialty Distribution
- Sector
- CANF Health Care
- RVLV Consumer Discretionary
- Exchange
- CANF Nasdaq
- RVLV Nasdaq
- Market Cap
- CANF 7.9M
- RVLV N/A
- IPO Year
- CANF N/A
- RVLV 2019
- Fundamental
- Price
- CANF $1.13
- RVLV $20.42
- Analyst Decision
- CANF Strong Buy
- RVLV Buy
- Analyst Count
- CANF 2
- RVLV 14
- Target Price
- CANF $14.00
- RVLV $28.79
- AVG Volume (30 Days)
- CANF 423.1K
- RVLV 1.6M
- Earning Date
- CANF 05-06-2025
- RVLV 05-06-2025
- Dividend Yield
- CANF N/A
- RVLV N/A
- EPS Growth
- CANF N/A
- RVLV 81.03
- EPS
- CANF N/A
- RVLV 0.70
- Revenue
- CANF $674,000.00
- RVLV $1,129,911,000.00
- Revenue This Year
- CANF $461.72
- RVLV $10.98
- Revenue Next Year
- CANF N/A
- RVLV $8.77
- P/E Ratio
- CANF N/A
- RVLV $29.35
- Revenue Growth
- CANF N/A
- RVLV 5.73
- 52 Week Low
- CANF $1.22
- RVLV $14.88
- 52 Week High
- CANF $4.69
- RVLV $39.58
- Technical
- Relative Strength Index (RSI)
- CANF 35.40
- RVLV 46.20
- Support Level
- CANF $1.14
- RVLV $19.72
- Resistance Level
- CANF $1.27
- RVLV $21.40
- Average True Range (ATR)
- CANF 0.12
- RVLV 1.52
- MACD
- CANF -0.02
- RVLV 0.26
- Stochastic Oscillator
- CANF 0.00
- RVLV 59.24
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).